Estradiol cypionate/testosterone cypionate: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Next edit →
Content deleted Content added
VisualWikitext
←Created page with '{{Drugbox | image = Estradiol 17 beta-cypionate.svg | width = 250px | caption = | image2 = Testosterone cypionate.svg | width2 = 235px | caption2 = Estradiol...'
(No difference)

Revision as of 00:57, 3 June 2019

Estradiol cypionate /
testosterone cypionate
Estradiol cypionate (top) and
testosterone cypionate (bottom)
Combination of
Estradiol cypionateEstrogen
Testosterone cypionateAndrogen; Anabolic steroid
Clinical data
Trade namesDepo-Testadiol, Femovirin, others
Other namesEC/TC
Routes of
administration		Intramuscular injection

Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination formulation of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women.[1] It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e., hot flashes), but can also be used for other estrogen indications in women.[1] The medication has also been used to suppress lactation in postpartum women.[2]

Depo-Testadiol is provided in the form of 10 mL vials containing 2 mg/mL EC and 50 mg/mL TC in an oil solution and is administered by intramuscular injection once every 4 weeks.[1] Conversely, Femovirin was provided in the form of 1 mL ampoules containing 3.5 mg/mL EC (2.4 mg/mL free estradiol) and 90 mg/mL TC (62.9 mg/mL free testosterone) in an oil solution and was administered by intramuscular injection once every 4 to 6 weeks.[3][4][5][6][7] The elimination half-life of EC in oil by intramuscular injection is approximately 5 days, while the elimination half-life of TC in oil by intramuscular injection is approximately 8 days.[1]

EC/TC likely poses a considerably increased risk of endometrial hyperplasia and cancer in women with intact uteruses (i.e., women who are not hysterectomized) if it is not combined with a progestogen.[1] This is due to the EC component.[1] The concomitant use of a progestogen will abolish such risks.[1] The medication can also cause masculinization, such as acne, deepened voice, hirsutism, and increased sex drive, due to its TC component.[1] Some of these masculinizing symptoms, such as voice deepening, can irreversible.[1]

Depo-Testadiol was introduced for medical use in 1954,[8] while Femovirin was introduced for medical use in 1956.[9] An oral tablet product with the same brand name of Femovirin, containing ethinylestradiol and methyltestosterone, was marketed in 1958, and should not be confused with the injectable Femovirin.[10]

Both Depo-Testadiol and Femovirin have been discontinued in the United States and most other countries, but formulations of EC/TC under other brand names continue to be marketed in Paraguay and Taiwan.[11][12][13]

Androgen replacement therapy formulations and dosages used in women
Route Medication Major brand names Form Dosage
Oral Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg 1x/1–2 days
Methyltestosterone Metandren, Estratest Tablet 0.5–10 mg/day
Fluoxymesterone Halotestin Tablet 1–2.5 mg 1x/1–2 days
Normethandronea Ginecoside Tablet 5 mg/day
Tibolone Livial Tablet 1.25–2.5 mg/day
Prasterone (DHEA)b – Tablet 10–100 mg/day
Sublingual Methyltestosterone Metandren Tablet 0.25 mg/day
Transdermal Testosterone Intrinsa Patch 150–300 μg/day
AndroGel Gel, cream 1–10 mg/day
Vaginal Prasterone (DHEA) Intrarosa Insert 6.5 mg/day
Injection Testosterone propionatea Testoviron Oil solution 25 mg 1x/1–2 weeks
Testosterone enanthate Delatestryl, Primodian Depot Oil solution 25–100 mg 1x/4–6 weeks
Testosterone cypionate Depo-Testosterone, Depo-Testadiol Oil solution 25–100 mg 1x/4–6 weeks
Testosterone isobutyratea Femandren M, Folivirin Aqueous suspension 25–50 mg 1x/4–6 weeks
Mixed testosterone esters Climacterona Oil solution 150 mg 1x/4–8 weeks
Omnadren, Sustanon Oil solution 50–100 mg 1x/4–6 weeks
Nandrolone decanoate Deca-Durabolin Oil solution 25–50 mg 1x/6–12 weeks
Prasterone enanthatea Gynodian Depot Oil solution 200 mg 1x/4–6 weeks
Implant Testosterone Testopel Pellet 50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

References

  1. ^ a b c d e f g h i http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.703.5708&rep=rep1&type=pdf
  2. ^ Vorherr H (July 1972). "Suppression of postpartum lactation". Postgrad Med. 52 (1): 145–52. doi:10.1080/00325481.1972.11713186. PMID 5037562.
  3. ^ Fr. Kauffmann (1959). Fünfundsechzigster Kongress: Gehalten zu Wiesbaden vom 6.–9. April 1959. Springer-Verlag. pp. 162–166. ISBN 978-3-642-96026-0.
  4. ^ Hans Hermann Julius Hager; Walther Kern; Paul Heinz List; Hermann Josef Roth (29 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 156, 185. ISBN 978-3-662-25655-8.
  5. ^ A. Saure (11 November 2013). Die Wechseljahre der Frau: Hormone — Präparate — Therapien. Springer-Verlag. pp. 157–. ISBN 978-3-0348-6676-7.
  6. ^ Georg Arends; Heinrich Zörnig; Hermann Hager; Georg Frerichs, Walther Kern (14 December 2013). Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1164–. ISBN 978-3-662-36329-4.
  7. ^ E. Buchborn; H. Jahrmärker; H.J. Karl; G.A. Martini, W. Müller, G. Riecker, H. Schwiegk, W. Siegenthaler, W. Stich (2 July 2013). Therapie innerer Krankheiten. Springer-Verlag. pp. 405–. ISBN 978-3-662-10489-7.{{cite book}}: CS1 maint: multiple names: authors list (link)
  8. ^ "NEW Prescription Products". Journal of the American Pharmaceutical Association (Practical Pharmacy ed.). 16 (3): 193–200. 1955. doi:10.1016/S0095-9561(16)33664-7. ISSN 0095-9561.
  9. ^ "Neue Spezialitäten". Klinische Wochenschrift. 34 (29–30): 819–819. 1956. doi:10.1007/BF01468058. ISSN 0023-2173.
  10. ^ "Neue Spezialitäten". Klinische Wochenschrift. 36 (24): 1169–1169. 1958. doi:10.1007/BF01481649. ISSN 0023-2173.
  11. ^ https://www.drugs.com/international/estradiol.html
  12. ^ Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN 978-0-85369-840-1.
  13. ^ https://www.micromedexsolutions.com/



Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Estradiol_cypionate/testosterone_cypionate&oldid=900037908"